The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Bosutinib (BOS) as third-line therapy for chronic phase (CP) chronic myeloid leukemia (CML) following failure with imatinib (IM) and dasatinib (DAS) or nilotinib (NIL).
T. H. Brummendorf
Consultant or Advisory Role - Bristol-Myers Squibb; Novartis; Pfizer
Honoraria - Bristol-Myers Squibb; Novartis; Pfizer
Research Funding - Bristol-Myers Squibb; Novartis; Pfizer
J. E. Cortes
Consultant or Advisory Role - Bristol-Myers Squibb; ChemGenex; Novartis; Pfizer
Research Funding - ARIAD; Bristol-Myers Squibb; ChemGenex; Novartis; Pfizer
H. Kantarjian
Research Funding - Bristol-Myers Squibb; Novartis; Pfizer
C. Gambacorti-Passerini
Consultant or Advisory Role - Bristol-Myers Squibb; Pfizer
Honoraria - Wyeth
Research Funding - Wyeth
M. Baccarani
No relevant relationships to disclose
D. Kim
Consultant or Advisory Role - Pfizer
Research Funding - Pfizer
A. Zaritskey
No relevant relationships to disclose
J. Navarro
No relevant relationships to disclose
A. Rapoport
No relevant relationships to disclose
P. E. Dorlhiac-Llacer
Research Funding - Bristol-Myers Squibb; Novartis; Pfizer; Wyeth
J. Milone
No relevant relationships to disclose
M. Zanichelli
No relevant relationships to disclose
N. Besson
Employment or Leadership Position - Pfizer
E. Leip
Employment or Leadership Position - Pfizer
V. Kelly
Employment or Leadership Position - Pfizer
H. J. Khoury
No relevant relationships to disclose